Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 35Bevacizumab 31Carboplatin 29pembrolizumab 25Specimen Handling 20Magnetic Resonance Spectroscopy 18olaparib 16Cisplatin 15liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 8fludarabine 7Doxorubicin 7mirvetuximab soravtansine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4durvalumab 4cediranib 4Platinum 4Megestrol Acetate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Panitumumab × Gynecologic × 30 days × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡